Minimum standards were met for patients with invasive cancer who received a single surgery for the primary tumor—83.9% (95% CI 78–90%)—and for patients with invasive breast cancer <3 cm in size (including DCIS component) who underwent breast-conserving treatment as primary treatment (excluding BRCA1 and BRCA2 patients)—65.7% (95% CI 58–74%). This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.